Processa Pharmaceuticals Inc. (PCSA) Next Earnings Date & Expected ±12.5% Move

Per the Roarable RQD rating, PCSA scores 39 out of 100 and receives a letter grade of D-, labeled "Roarable Sell — Vulnerable Balance Sheet & Flow." Across the five pillars:

• Fundamental cash engine: 7 / 20. The pillar notes ROIC of -35% and an FCF yield of 0%. For a prospective investor, this indicates the business is not currently generating returns on invested capital or free cash flow to offset its reported losses.
• Whale 13F flow: 8 / 20. The pillar summarizes institutional accumulation and options positioning. The underlying holder detail is not provided in this dataset, so the score reflects the rating's assessment without itemized support here.
• Insider conviction: 5 / 20. The lowest pillar, covering SEC Form 4 and Congressional PTR cluster flow. A low score signals weak insider-level conviction signals in the rating's inputs.
• Macro regime fit: 9 / 20. The pillar cites beta of 1.0 and sector sensitivity. A beta of 1.0 means the stock is modeled to move in line with the broader market, offering no defensive cushion.
• Forensic balance sheet: 10 / 20. The pillar references Altman Z of 2.5, Piotroski F of 2/9, and Debt/Equity of 0.5. These metrics sit in the middle-to-weak range and point to a balance sheet that warrants close monitoring.

Taken together, the rating frames PCSA as a high-risk, cash-consuming equity where the upside case depends on events outside the current financial profile. Valuation tradeoffs are significant: with a market capitalization of $5.3M and no reported positive earnings, traditional earnings-based valuation is not available in source data. Upside drivers would need to come from pipeline progress and corporate actions rather than current operations.

Processa Pharmaceuticals Inc. is a NASDAQ-listed issuer in the Health Care sector, classified under Biotechnology: Pharmaceutical Preparations. Per the company profile, the market capitalization is listed as $0.0B. Specific product lines, customer base, and revenue model are not available in source data. Per the SEC financials, reported revenue was $0.0M in each of FY 2023, FY 2024, and FY 2025, indicating no reported revenue in the periods provided. Per recent news, the company has announced a pipeline item (a BTK inhibitor, VT-7208) and a merger with Vidya Therapeutics; details beyond these headlines are not available in source data.

Per the SEC financials, the company reported operating losses and net losses in each period shown, with gross, operating, and net margins all listed at 0% in market data. Per the Roarable RQD rating, ROIC is -35%. The Altman Z-Score of 2.5 and Piotroski F-Score of 2/9 are cited within the forensic balance sheet pillar; the Piotroski score is weak. Debt/Equity is listed as 0.5. Reported cash rose from $1.2M (FY 2024) to $5.5M (FY 2025), while FCF remained negative in every period.

• Green catalyst (per Kalkine): Clearance of an FDA IND for the BTK inhibitor VT-7208 in urticaria, alongside a Generian partnership, flagged as a pipeline expansion.
• Yellow market-wire items: Several reports (Yahoo Finance Canada, TradingView, Stock Titan, Kalkine Media, GlobeNewswire) cover a proposed reverse stock split following the Vidya Therapeutics merger and corporate/pipeline progress updates. A reverse split is a structural corporate action; its implications for share count and price are not detailed in source data.
• Risk watch: The reverse split proposal and the weak balance sheet metrics are the primary items to monitor. Per the market data, the stock trades at $1.89 against a 52-week high of $10.25.
• Proprietary signals: None provided in the Butterfly Supply-Chain Graph.

Per the Butterfly Supply-Chain Graph, the supply chain is listed as "NONE," with no butterfly links and no proprietary signals. Upstream and downstream dependencies, sector correlations, and second-order bottlenecks are not available in source data. An investor should note that the pipeline (VT-7208) and the Vidya merger are the company's main external linkages per the news wire, but their supply-chain relationships are not mapped in the provided graph.

• What is the company's revenue model and does it expect any product revenue, given $0.0M reported in each period?
• What are the terms, share count impact, and timing of the proposed reverse stock split and the Vidya Therapeutics merger?
• What is the current cash runway relative to the FY 2025 FCF of $-11.4M, and how will the company fund operations?
• What are the terms and milestones of the Generian partnership and the VT-7208 development program?
• Who are the institutional and insider holders behind the RQD pillar scores, given that the holders dataset is empty?